Sanofi
Dupixent
chronic spontaneous urticaria
Resolved
97days ago
FDA decision · Apr 1, 2026
What's at stake
The FDA's approval decision on Dupixent for chronic spontaneous urticaria is due Apr 1, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 11h ago
“The US Food and Drug Administration decision is expected by April 2026.”